Hafslund And Byk Gulden Settle Dispute
Hafslund Nycomed of Norway and German company Byk Gulden have resolved their longstanding dispute concerning marketing rights in certain European markets to contrast agents for magnetic resonance imaging originating from Hafslund Nycomed's US subsidiary, Nycomed Salutar.
Byk Gulden has renounced all rights to these products, against payment of an undisclosed sum. Also, Byk Gulden will return to Hafslund Nycomed all rights to S-095, an MRI product for liver imaging.
Meantime, in Spain, Hafslund Nycomed is to sell the therapeutics and over-the-counter business of its Spanish subsidiary, Nycomed Leo, to Elmuquimica, a subsidiary of Byk Gulden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze